The LiverMultiScan-cT1 is an MRI-derived noninvasive tissue biomarker that the company said identifies patients in biochemical remission and patients in deep remission with undetected, active subclinical disease at a high risk of disease relapse.

The study was led by researchers from Kings College Hospital and Oxford University Hospitals. Perspectum said it showed that cT1 measurements obtained with the LiverMultiScan outperformed blood biomarkers and FibroScan in identifying patients likely to experience disease progression, despite being in biochemical remission.